Gait as Predictor of Dementia and Falls. The Gait and Brain Cohort Study
Launched by MANUEL MONTERO ODASSO · Jan 11, 2017
Trial Information
Current as of September 14, 2025
Recruiting
Keywords
ClinConnect Summary
The Gait and Brain Cohort Study is a clinical trial that aims to understand how the way older adults walk can help predict their risk of developing dementia and experiencing falls. As people age, both their thinking and movement can slow down, and when both happen together, the risk of dementia increases significantly. The researchers believe that by observing small changes in a person's walking pattern while they perform a simple task, they can identify older adults who might be at a higher risk for dementia and mobility issues.
To participate in this trial, individuals must be between 60 and 85 years old and able to walk independently for a short distance without any walking aids, like a cane or walker. They should not have dementia or certain other medical conditions that could affect their walking. Participants will undergo assessments that include observing their gait, which could help in creating strategies to prevent or delay dementia and related mobility problems in the future. This study is particularly important as it addresses the growing number of older adults in Canada and aims to improve their quality of life while reducing the burden on the healthcare system.
Gender
ALL
Eligibility criteria
- General Inclusion Criteria:
- • Absence of Dementia (DSM IV-TR or DSM V criteria)
- • Aged 60-85 years
- • Able to walk independently 10 meters without any gait aid (for example: walker, cane);
- Exclusion Criteria:
- • Unable to understand English;
- • Parkinsonism or any neurological disorder with residual motor deficit (e.g.: stroke, epilepsy);
- • Musculoskeletal disorder detected by clinical examination which affects gait performance;
- • Active osteoarthritis affecting the lower limbs at clinical evaluation
- • Use of psychotropics which can affect motor performance (e.g. neuroleptics and benzodiazepines)
- • Severe Depression (score \> 12/15 on the Geriatric Depression Scale).
About Manuel Montero Odasso
Manuel Montero Odasso is a distinguished clinical trial sponsor known for his commitment to advancing medical research and improving patient outcomes. With a focus on innovative therapies and evidence-based practices, he leads a team dedicated to conducting rigorous clinical trials that adhere to the highest ethical and scientific standards. His expertise in geriatrics and neurodegenerative diseases drives the development of novel interventions, aiming to enhance the quality of life for aging populations. Through collaborative efforts with research institutions and healthcare professionals, Montero Odasso strives to bridge the gap between laboratory discoveries and clinical application, ensuring that promising findings translate into effective treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, Ontario, Canada
Patients applied
Trial Officials
Dr. Manuel Montero Odasso, M.D.
Principal Investigator
Director, Gait and Brain Lab
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials